Urolithin A vs CoQ10
Both target mitochondrial aging — but at completely different points in the process
The bottom line
Urolithin A vs CoQ10: which is better?
Choose urolithin A if your primary goal is clearing dysfunctional mitochondria via mitophagy — especially post-45 with fatigue or declining muscle function. Choose CoQ10 if you are on a statin (obligatory repletion), have cardiovascular history, or want ETC support with strong safety data. Stack both for comprehensive mitochondrial coverage.
What this is
Head-to-head evidence table: Urolithin A vs CoQ10 (Ubiquinol) (compound).
Why it matters
Urolithin A and CoQ10 are frequently compared as "mitochondrial supplements" — but they operate at entirely different levels of mitochondrial biology. CoQ10 is an electron transport chain cofactor: it fuels existing mitochondria by shuttling electrons between Complex I/II and Complex III. Urolithin A activates mitophagy: it removes the damaged mitochondria that can no longer function well enough for CoQ10 to help. These are not competing interventions — they are complementary. The question is which problem you are solving first.
What to do next
Use the verdict row to pick a primary compound, then open both deep-dives and /shop verification checklists.
Urolithin A and CoQ10 are frequently compared as "mitochondrial supplements" — but they operate at entirely different levels of mitochondrial biology. CoQ10 is an electron transport chain cofactor: it fuels existing mitochondria by shuttling electrons between Complex I/II and Complex III. Urolithin A activates mitophagy: it removes the damaged mitochondria that can no longer function well enough for CoQ10 to help. These are not competing interventions — they are complementary. The question is which problem you are solving first.
Verdict scorecard
10 dimensions compared
Mechanism
Upstream (cleanup) vs downstream (fuel) — orthogonal, not competing
Urolithin A
PINK1/Parkin mitophagy activation — removes damaged mitochondria
CoQ10 (Ubiquinol)
ETC electron shuttle at Complex I/II → III — fuels existing mitochondria
Human trial evidence
Both have Tier A-level evidence in their respective primary endpoints
Urolithin A
Phase 2 RCT (Ryu 2022, PMID 35391504) — muscle strength and mitophagy gene expression confirmed in biopsy
CoQ10 (Ubiquinol)
Meta-analysis 17 RCTs (Liang 2016, PMID 26267690) — hs-CRP and IL-6 reduction; Q-SYMBIO RCT for heart failure
Statin users
If on any statin, CoQ10 is the priority. Non-negotiable repletion.
Urolithin A
Not indicated for statin depletion
CoQ10 (Ubiquinol)
Obligatory — statins block HMG-CoA reductase which synthesizes CoQ10 endogenously
Muscle function (≥65)
Urolithin A
Phase 2 RCT primary endpoint: significant improvement in handgrip and leg press
CoQ10 (Ubiquinol)
Indirect — ETC support contributes to muscle energy but not primary endpoint
Cardiovascular benefit
Urolithin A
Not primary indication
CoQ10 (Ubiquinol)
Q-SYMBIO: 43% MACE reduction in heart failure; REDUCE-IT context (CoQ10 membrane + omega-3)
Dietary accessibility
UA requires standardized Mitopure to bypass gut conversion limitation
Urolithin A
Only ~40% of people have gut microbiome to produce UA from food — supplement dependency high
CoQ10 (Ubiquinol)
Endogenous synthesis possible; ubiquinone in many foods; but declines with age
Fat co-ingestion requirement
Both are fat-soluble; breakfast is the ideal timing for both
Urolithin A
Yes — take with fat-containing meal
CoQ10 (Ubiquinol)
Yes — lipid-soluble, requires dietary fat
Senescent cell coverage
Urolithin A's mitophagy mechanism has a more direct senescence pathway link
Urolithin A
Indirect — mitophagy reduces mitochondria-driven ROS that promotes senescence
CoQ10 (Ubiquinol)
Indirect — ROS reduction via ETC efficiency reduces senescence trigger signals
Safety profile
Urolithin A
Phase 1 + 2: no serious adverse events at 250–2000 mg across 5 months
CoQ10 (Ubiquinol)
Decades of clinical use; excellent profile; warfarin interaction at high dose
Cost-effectiveness
For budget-constrained stacks, CoQ10 delivers strong ETC support at lower cost
Urolithin A
Mitopure is premium — standardization is essential but carries premium pricing
CoQ10 (Ubiquinol)
Generic ubiquinol well-characterized; CoQ10 cost has fallen significantly
Choose Urolithin A when
- Age ≥45 with declining muscle recovery, endurance, or unexplained fatigue
- Building a senescence/healthspan protocol — mitophagy clearance as the core mechanism
- Not on statins — the statin-depletion rationale for CoQ10 does not apply
- Adding to an NMN stack — urolithin A clears damaged mitochondria that NMN alone cannot rehabilitate
- Low dietary urolithin A conversion suspected (most Western adults fall in this category)
Choose CoQ10 (Ubiquinol) when
- On any statin medication — CoQ10 repletion is obligatory, not optional
- Cardiovascular disease history — Q-SYMBIO data supports MACE reduction in HF
- Muscle fatigue or myalgia on statins — the most actionable CoQ10 use case
- Budget-constrained — CoQ10 delivers Tier B mitochondrial support at substantially lower cost than Mitopure